Abstract Background: The anti-angiogenic Sorafenib is the only approved systemic therapy
for advanced hepatocellular carcinoma (HCC). However, acquired resistance limits its …

The approval of sorafenib as the first effective drug for the treatment of hepatocellular
carcinoma (HCC) represents a milestone in the treatment of this disease. A better …

Background Post‐operative liver regeneration may contribute to tumor recurrence. There is
a theoretical need for an adjuvant therapy that can suppress tumor growth without adversely …

Background The combination of bevacizumab (B) and erlotinib (E) has shown promising
clinical outcomes as the first-line treatment of advanced HCC patients. We aimed to evaluate …

Resistance is one limitation of sorafenib in the treatment of hepatocellular carcinoma (HCC).
Insulin-like growth factor-1 receptor (IGF-1R) is involved in cancer cell proliferation. To …

Purpose Severe adverse events frequently occur in patients treated with sorafenib, whereas
some patients have suboptimal response to sorafenib. We aimed to evaluate the association …

The limited availability of experimental tumor models that faithfully mimic the progression of
human tumors and their response to therapy remains a major bottleneck to the clinical …

Purpose: Novel therapeutic strategies are needed to prevent the tumor recurrence or
metastasis after liver transplantation for hepatocellular carcinoma (HCC). This study was to …

Primary liver cancer is the fifth most common cancer worldwide and the third most common
cause of death from cancer, resulting in more than 600,000 deaths per year. The major risk …

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality
worldwide. The AKT pathway is often activated in HCC cases, and a longer exposure to …